Retinoid class drugs

14 results

  • absorica

    (isotretinoin)
    Sun Pharmaceutical Industries, Inc.
    ABSORICA and ABSORICA LD are indicated for treating severe recalcitrant nodular acne in non-pregnant patients aged 12 and older, unresponsive to conventional therapies. A two-month waiting period is recommended before a second course, as acne may continue to improve after initial treatment.

  • accutane

    (ISOTRETINOIN)
    JG Pharma Inc.
    Accutane is indicated for severe recalcitrant nodular acne in patients unresponsive to conventional therapy, including systemic antibiotics. It is contraindicated in pregnant patients due to potential life-threatening birth defects. A single 15 to 20-week treatment course may lead to prolonged remission.

  • aklief

    (trifarotene)
    Galderma Laboratories, L.P.
    AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.

  • altreno

    (tretinoin)
    Bausch Health US, LLC
    ALTRENO® (tretinoin) lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.

  • arazlo

    (tazarotene)
    Bausch Health US, LLC
    ARAZLO® (tazarotene) lotion, 0.045% is indicated for the topical treatment of acne vulgaris in patients aged 9 and older.

  • duobrii

    (halobetasol propionate and tazarotene)
    Bausch Health US, LLC
    DUOBRII® (halobetasol propionate and tazarotene) Lotion is indicated for the topical treatment of plaque psoriasis in adults.

  • epiduo

    (adapalene and benzoyl peroxide)
    Galderma Laboratories, L.P.
    EPIDUO gel is indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.

  • fabior

    (tazarotene)
    Mayne Pharma
    FABIOR® (tazarotene) Foam, 0.1% is indicated for the topical treatment of acne vulgaris in patients aged 12 years and older.

  • retin-a micro

    (Tretinoin)
    Bausch Health US LLC
    Retin-A Micro® is a retinoid indicated for topical use in the treatment of acne vulgaris.

  • sohonos

    (palovarotene)
    Ipsen Biopharmaceuticals, Inc.
    SOHONOS is indicated for reducing the volume of new heterotopic ossification in adults and pediatric patients with fibrodysplasia ossificans progressiva (FOP), specifically in females aged 8 years and older and males aged 10 years and older.